



ScinoPharm Taiwan, Ltd.

Ticker: TWSE 1789

ScinoPharm Management Presentation

March 14, 2017



Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein.

The **information contained** in this presentation is ScinoPharm’s **confidential** information. Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this presentation include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Table of Contents

- **Overview of ScinoPharm**
- **Financial & Operating Results in FY2016**
- **Business Updates**

Overview of ScinoPharm

Business Overview

- Company specializes in high potency (steroid/cytotoxic) APIs and is expanding into sterile/aseptic injectable formulations
- Facility & organization established in Taiwan and expanding in China with a new GMP plant in Changshu & marketing base in Shanghai
- 72 generic APIs in current portfolio with 25 APIs launched; 53 US DMFs filed (757 DMFs WW), 32 US DMFs in oncology APIs. 100+ NCE CRAM projects, with 5 APIs launched and 5 in phase III for NDA filing in 1-3 years
- Fully compliant with world-class cGMPs and international regulatory requirements; Certified by US FDA, EMA, EDQM, Australian TGA, Japanese PMDA

World Class API Facilities

Taiwan

- 6.6 hectares of land, 330K sq.ft. facilities with $>200\text{M}^3$ reactor volume
- 5 of 16 production lines equipped with high potency capabilities for cytotoxic/steroids
- Passed US FDA, EMA, EDQM, Australian TGA, Japanese PMDA inspections, & 300+ cGMP customer audits
- Provides comprehensive contract research & manufacturing services for brand drug companies
- Global Market




China

- 6.7 hectares of land with $> 250\text{M}^3$ reactor volume
- 3 of 7 production lines equipped with high potency capabilities for cytotoxics
- US FDA approved cGMP facility for intermediates & high potency API
- Full scope capabilities in the development and production of APIs on small to large scales for generic & CRAM markets
- Global market including China



Strong Generics Product Portfolio




Note: Other (Women's Health, Gastrointestinal, Immunology and Metabolic)




TWSE 1789

ScinoPharm - Oncology API Leader

Stand-Alone API Companies



Large Generic Pharmaceutical Companies




Source: US FDA DMF Q3 2016 database



TWSE 1789

We are Transforming our Company



Keys to Generic Formulation Business

Opportunity	Strategy	Tactics
<ul style="list-style-type: none">✓ Already the leader in providing oncology APIs to regulated markets worldwide✓ Injectable CMOs are in short supply.✓ Can be customer's injectables provider by developing formulations using our own oncology APIs or others' APIs, up to and including ANDA filing with FDA	<ul style="list-style-type: none">✓ Developing dossiers per our difficult-to-make APIs to increase value proposition in the supply chain✓ Targeted delivery & extended release of proven APIs via 505(b)(2) fast track✓ Collaborating with start-ups & research institutes, focusing on un-met oncology medical needs of high prevalence in Asia	<ul style="list-style-type: none">✓ Expanding formulation portfolio✓ Establishing on-site oncology injectable facility and providing an integrated supply chain✓ Promoting our formulations via strategic alliances, especially in China and US/EU



Financial & Operating Results in FY2016

Profit & Loss - Consolidated

In NT\$ million, except for EPS	FY 2016 (Unaudited)	FY 2015 (Audited)	YoY
Operating Revenue	4,031	3,955	2%
Gross Profit	1,806	1,677	8%
<i>Gross margin</i>	<i>45%</i>	<i>42%</i>	
Operating Expenses	(938)	(927)	1%
Operating Income	868	750	16%
<i>Operating margin</i>	<i>22%</i>	<i>19%</i>	
Other Rev. (Exp.)	(57)	* 53	-208%
Net Income before Tax	811	803	1%
Net Income after Tax	659	635	4%
<i>Net margin after tax</i>	<i>16%</i>	<i>16%</i>	
EPS (after tax)	0.87	0.84	4%

* One-time capital gains in 2015 of NT\$95 MM is a result of the equity swap with Foresee. Without this item, the Net Income after Tax YOY % would be 19%.

Balance Sheet- Consolidated

In NT\$ million	2016/12/31 (Unaudited)		2015/12/31 (Audited)	
Cash and Cash Equivalents	3,707	29%	2,336	19%
Accounts Receivable	638	5%	867	7%
Inventories	1,830	18%	2,169	18%
Long-Term Investments	364	3%	339	3%
Property, Plant & Equipment	5,209	42%	5,171	42%
Other Current/Non-Current Assets	1,035	11%	1,340	11%
Total Assets	12,783	100%	12,222	100%
Current Liabilities	1,692	13%	2,275	18%
Long-Term & Other Liabilities	863	7%	90	1%
Stockholders' Equities	10,228	80%	9,857	81%

Cash Flows- Consolidated

In NT\$ million	FY 2016 (Unaudited)	FY 2015 (Audited)
Cash and cash equivalents at beginning of period	2,336	1,928
Cash flows from operating activities	1,659	764
CAPEX	(437)	(582)
Short-term borrowings	(720)	402
Long-term borrowings	803	-
Cash Dividends	(219)	(141)
Others	285	(525)
Cash and cash equivalents at end of period	3,707	1,846

Free Cash flow

1,222

388




ScinoPharm


TWSE 1789

Sales by Business



FY2015



FY2016




Sales by Indication




Sales by Region

FY2015



FY2016



Business Updates

Business Growth Drivers

- **CRAM has promising development potential in the next three years**
 - Focus on small-molecule targeted therapies and CNS agents based on new mode of action
 - Provide integrated service from API to formulation for niche injectables
- **Active development of Chinese and Japanese market**
 - Target projects to utilize capacity and accelerate growth for Changshu site
 - Develop partnership with major Japanese pharmaceutical companies and international pharmaceutical groups with Japan-based operation site
- **Deploying the network of development, production and distribution of injectable products**
 - Build partnerships to speed up the momentum of vertical integration
 - Achieve critical mass workforce for in-house injectable plant facility
- **Continue optimizing existing generic APIs**
 - Maintain the market share and profit of the top 5 marketed products

Trend of New Oncology Agents

The development of genomics and molecular biology sheds light on new concepts of cancer therapy

- Cancer was regarded as a single disease and was primarily managed by killing cancer cells with high dose of cytotoxic substances (chemotherapy or radiotherapy).
- With the understanding individual genomic variance, immunity integrity, and tumor development, more mechanisms have been developed to provide high specificity agents with less toxicity. The control of tumor growth and progression can be tailored to individual conditions.
- **Oral small-molecule targeted chemotherapy** is currently one of the primary areas of novel anti-cancer agents.

CRO Phase III Product Portfolio

* Already Filed

Code	Est. NDA Filing Year	Indication	Region	*Regional Sales	Remarks
A	2016*	Infectious Disease	US / EU / Asia	\$1.4 bn	Completed process validation. Anticipated launch in 2017 with demand in tons. Expected revenue of several million USD per year
B	2017	Ovarian Cancer Endometrial Cancer	US / EU	\$6.0 bn	Anticipated launch in 2018 and revenue of several million USD within 3 years
C	2018	Type I,II Diabetes	US/ EU	\$2.4 bn	Intermediate project made in Changshu site. Expected revenue of several million USD per year after launch
D	2018	Advanced Hepatocellular Carcinoma, Myelofibrosis, Autoimmune disease, etc.	CN	N/A	API project made in Changshu site. CFDA granted accelerated review under its category 1.1 innovative drug. Anticipated launch in 2019 with demand in tons

* Source: BioMedTracker, GlobalData and DataMonitor

CRO Phase III Product Portfolio (cont'd)

Code	Est. NDA Filing Year	Indication	Region	*Regional Sales	Remarks
E	2018	Prostate Cancer	US / EU	\$2.4 bn	Started process validation. Anticipated launch in 2019 and revenue of several million USD per year
F	2018	Parkinson's Disease	US	\$1.0 bn	Novel mechanism with promising demand. Anticipated launch in 2019 with demand in tons. Expected revenue of several million USD per year

 ***CRAM business is expected to enjoy significant growth in 2017***

* Source: BioMedTracker, GlobalData and DataMonitor

China and Japan Market Development

China

- Accelerate progress to create positive cash flow
- Focus on mid- to late-phase CRO projects. Current portfolio includes agents for oncology, anti-hypertension, and diabetes
- Seek generic APIs/intermediates with large demand to increase production utilization
- Develop partnerships with downstream formulation for collaborative development and registration, realizing shared profit creation

Japan

- Among 20 customers, 6 are top 10 drug firms. Less established players have exited the more concentrated market
- Encourage local generic customers to engage more in direct business
- Support Japanese companies and foreign pharmaceutical companies to enable and extend business outreach
- With the resources in Taiwan and Changshu, API supply is more flexible and can be incorporated to injectable drug product via integrated services



TWSE 1789

Selected List of CRAM Projects at Changshu

Customer	Project Type	Product Indication/stage	Product Type	Remarks/ Market
Top 10 global pharma	CMO	Approved antidepressant drug in US	GMP Intermediate	Passed Mexican authority (APIF) GMP inspection
Top 5 global pharma	CMO	Approved African sleeping disease drug	API	Site transfer from Taiwan
Lee's Pharma	CRO / CMO	>15 projects for brain tumors, antibiotic, hypertension, ophthalmology, etc.	API	China
China pharm company	CRO	Phase II/ III clinical trial for cancer	API	China
China pharm company	CRO	Phase IIb for age-related macular degeneration	API	US/China
Taigen Biotech	CRO	Phase II clinical trial for myocardial infarction	API	China/Taiwan
US-based new drug company	CRO	Phase II clinical trial for prevention of HIV infection	API	US
Aslan Pharmaceuticals	CRO	Phase II clinical trial for cancer	API	China/Global
Top 5 global pharma	CRO	Phase III clinical trial for diabetes	Intermediate	US
Top 5 global pharma	CRO	Phase I clinical trial	API	NA
US NASDAQ listed pharma	CRO	Phase III clinical trial for opioid-induced constipation	Crude API	US
US-based new drug company	CRO	Phase I clinical trial for sickle cell disease	API	US

Formulation Business Progress

In-house injectable plant

- On schedule to complete equipment assembly and verification, sterility verification, organization, personnel deployment and training, and cGMP system deployment for both vial and cartridge production lines
- Planned kick-off registration batch production by 2017. Expected submission of 1st in-house ANDA in 2018 and subsequent US FDA inspection approval in 2019.

Formulation and collaboration development

- 2 US ANDAs: Oncology product partnership with SAGENT, and ScinoPharm-developed Fondaparinux
- 11 co-developed and cost/profit sharing products with various partners
- Niche drugs planned with the indications of cancer, diabetes, osteoporosis, multiple sclerosis, and anti-emetics. Continue to develop strategic alliances, including ongoing discussions with international major companies for exclusive rights of distribution.



TWSE 1789

Strategic Alliance Highlights

* Already launched

Partner	Product	Indications	Region	Launch Year(E)	Remarks
Genovate	Entecavir	Hepatitis B Virus	Taiwan	2013*	1 st co-developed formulation product launch
Sagent	Oncology Injectable	Myeloid Leukemia	US	2017	1 st US ANDA filing, triggering US FDA inspection in Changshu, China site
Foresee	Leuprolide	Prostate cancer	US	2019	505(b)(2) NDA CRAM + Equity
Coland	Bortezomib	Multiple Myeloma	China	2020	1 st co-developed drug in China to trigger CFDA inspection in Changshu site
	Azacitidine	MDS	China	2021	Co-developed formulation in China
Lee's Pharma	Fondaparinux	Anti-thrombotic	China	2021	Co-development collaboration
	Travoprost Bimatoprost	Glaucoma	China	2021	
Nanjing King Friend	Regadenoson	Stress agent for heart scan	China	2020	Co-developed formulation in China
US partner	Project A	Non-small cell lung cancer	US	2018	US NDA 505(b)(2) with Paragraph IV filing / The estimated launch year is subject to litigation results
US & China partners	Project B	Imaging agent	US	2021	ANDA with Paragraph IV filing / The estimated launch year is subject to litigation results
Baxter	5 niche injectables	Anticancer & antinauseant	US/EU	2020& continuing thereafter	Baxter has the right to add up to 15 additional injectable products for collaboration

Injectable Products Allied with Baxter

- ScinoPharm and Baxter Healthcare establish worldwide partnerships to co-develop and commercialize five niche generic injectable products at the initial stage
- ScinoPharm develops all APIs and injectable formulations. Baxter leads regulatory submissions in the US/EU and eventually market & sell the injectable products via its extensive presence in the hospital channel
- Both parties work on a cost-and-profit-sharing collaboration model
- Baxter has the right to add up to 15 additional injectable products for collaboration with ScinoPharm

Collaboration Framework (con't)

- Initial product portfolio including the generic injectables for breast cancer, lung cancer, multiple myeloma and antinauseant. Targeting US/EU markets first and expect to expand to other territories
- This exclusive partnership will utilize each other's strengths and expertise in order to achieve large scale of synergies in providing niche and affordable generic injectable products
- Commercial launch for the first 5 products upon FDA approval, with product launches beginning in 2020 and continuing thereafter
- Current branded sales of the initial five products included in this partnership total more than \$4 billion annually



TWSE 1789

Benefits of the Collaboration

- Aggressively expanding our “Double A” strategy for in-house developed/produced APIs and formulations. Providing an outlet for our injectable plant capacity
- A win-win solution and collaboration. ScinoPharm provides comprehensive APIs and formulation portfolio, while Baxter operates strong injectable product marketing channels throughout the US and worldwide
- Accelerate the momentum of our downstream integration strategy by establishing alliance with an world-renowned partner

Maintain Market Share of Existing APIs

2016 Major Products account for 65% of total sales

API	Indication	2016 MKT share*	# of US DMF/EDMF & other filings
Irinotecan HCl	Antineoplastic	42%	63
Paclitaxel	Antineoplastic	34%	57
Gemcitabine	Antineoplastic	24%	76
Exemestane	Antineoplastic	22%	44
Galantamine HBr	Antipsychotic	17%	38
Docetaxel Anhydrous	Antineoplastic	15%	69

*Source: IMS data from Newport

2017 Product Launch Plan

Type	Product	Region	Indication	Brand Marketer	Regional Sales	WW Sales
Generic API	Desmopressin Acetate	USA	Polyuria	Ferring	US\$166M	US\$405M
Generic API	Tamsulosin HCl	USA	Benign Prostatic Hyperplasia (BPH)	Boehringer Ingelheim	US\$333M	US\$1706M
CMO API	Oral Product	USA EU	Antibiotics	N/A	N/A	N/A
Generic Drug	Oncology Injectable	US	Myeloid Leukemia	MDS	US\$183M	US\$278M

Source: IMS Data (2015Q3-2016Q2)

Pipeline Outlook

- ✓ 2 generic API launches
- ✓ 1st co-developed US ANDA launched

- ✓ 5-6 new launches
- ✓ 1 drug products launched in US
- ✓ Chinese (CFDA) inspection at Changshu site
- ✓ US FDA inspection at Injectable plant

2017

2018

2019

2020

- ✓ 3-5 generic API launches
- ✓ 1st in-house drug US ANDA filing
- ✓ 1st self-developed US ANDA launched
- ✓ 1 co-developed US ANDA launched

- ✓ 4-5 new launches
- ✓ 2 co-developed China ANDAs and 1 co-developed US ANDA launched



ScinoPharm

TWSE 1789

***Q*uestions**

&

***A*nswers**



Brand Quality with Asian Advantages

www.scinopharm.com



ScinoPharm

TWSE 1789